Company Overview
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.
Recent Developments
- Dec 2025 Revenue of $23.85M (+475.5% YoY); net profit $-175.09M.
- Trailing 12 Months Year-on-year growth — revenue +279.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 279.30% |
Stock Price Performance
| 1 Year: | -42.82% |
| 6 Months: | -38.85% |
| 3 Months: | -8.40% |
| 1 Month: | -30.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)32.71 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 67.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Basic Materials).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ASPI ASP Isotopes Inc. R2K | 4.58 | -2.07 | $576.64M | 0.00% | -12.29% | -103.32% | - | - |
| 2 | LIN Linde plc NDXSPX | 514.15 | 34.05 | $237.72B | 1.22% | 12.46% | 18.23% | 13.90% | 18.47% |
| 3 | NEM Newmont Corporation SPX | 95.21 | 12.35 | $101.64B | 1.10% | - | 25.83% | 6.53% | 20.15% |
| 4 | FCX Freeport-McMoRan Inc. SPX | 60.97 | 32.26 | $87.65B | 0.97% | 12.50% | 15.63% | 1.35% | -1.26% |
| 5 | SHW The Sherwin-Williams Company SPX | 332.29 | 31.92 | $81.95B | 0.97% | 21.93% | 60.72% | 6.18% | 8.26% |
| 6 | ECL Ecolab Inc. SPX | 270.25 | 36.57 | $76.06B | 1.07% | 14.29% | 22.43% | 6.17% | 9.18% |
| 7 | CRH CRH plc SPX | 103.96 | 19.04 | $69.47B | 1.52% | 10.97% | 15.81% | 6.41% | 9.30% |
| 8 | APD Air Products and Chemicals, Inc. SPX | 293.69 | 30.98 | $65.40B | 2.40% | -0.62% | 12.35% | -1.77% | -39.16% |
| 9 | CTVA Corteva, Inc. SPX | 84.45 | 46.15 | $56.48B | 0.84% | - | 5.14% | 2.86% | 9.94% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 840.35K | 1.02M | - | - | 1.10M | 1.20M | 4.89M | 16.66M | 4.18M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 775.00K | 626.25K | 4.47M | 14.58M | 2.51M |
| Gross Profit | - | - | - | 0 | 0 | 0 | 278.87K | 421.02K | - | - | 327.00K | 572.10K | 423.18K | 2.08M | 1.67M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 8.28M | 12.54M | 15.39M | 24.39M | 26.55M |
| Operating Income | -858.25K | -827.96K | -1.95M | -3.72M | -4.35M | -3.95M | -5.81M | -7.46M | - | - | -7.95M | -11.97M | -14.97M | -22.30M | -24.89M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -8.30M | -74.45M | -12.38M | -61.95M | -21.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 87.00K | 81.80K | 146.06K | 259.99K | 1.73M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -8.53M | -75.06M | -12.82M | -63.15M | -26.74M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | -71.00K | 95.24K | 73.63K | 183.85K | -31.00K |
| Net Income | -857.59K | -827.17K | -1.96M | -3.62M | -4.29M | -4.22M | -6.96M | -8.88M | - | - | -8.45M | -75.06M | -12.87M | -78.71M | -6.88M |
| Diluted EPS | - | - | -0.06 | - | - | -0.14 | -0.16 | -0.24 | -0.12 | - | -0.12 | -1.03 | -0.15 | - | -0.06 |
| R&D Expense | 293.05K | 153.39K | 745.46K | 207.33K | 252.88K | 239.20K | 215.13K | 473.30K | 1.03M | - | 1.53M | 879.92K | 3.10M | - | 5.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 433.03K | 4.14M | 23.85M |
| Cost of Revenue | 0 | 294.06K | 2.54M | 20.44M |
| Gross Profit | 0 | 138.97K | 1.60M | 3.40M |
| Operating Expenses | 5.10M | 16.18M | 27.95M | 60.60M |
| Operating Income | -5.10M | -16.04M | -26.35M | -57.19M |
| EBITDA | -4.95M | -16.14M | -31.58M | -157.07M |
| Interest Expense | 0 | 118.55K | 259.00K | 575.00K |
| Pretax Income | -4.95M | -16.30M | -32.31M | -159.56M |
| Tax Provision | 0 | -6.13K | 111.00K | 282.00K |
| Net Income | -4.95M | -16.29M | -32.33M | -175.09M |
| Diluted EPS | -0.18 | -0.49 | -0.63 | -2.11 |
| R&D Expense | 1.27M | 764.58K | 3.14M | 12.36M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 12.50M | 27.54M | 94.35M | 498.02M |
| Current Assets | - | - | 3.30M | 10.51M | 65.74M | 399.92M |
| Cash & Equivalents | - | - | 2.39M | 7.91M | 61.89M | 285.56M |
| Inventory | - | - | - | 0 | 66.00K | 1.10M |
| Receivables | - | - | 0 | 216.50K | 707.00K | 17.88M |
| Total Liabilities | - | - | 2.68M | 8.71M | 43.18M | 235.12M |
| Current Liabilities | - | - | 1.94M | 5.67M | 7.06M | 32.70M |
| Long Term Debt | - | - | - | - | 34.87M | 200.79M |
| Total Debt | - | - | 822.20K | 2.14M | 37.74M | 215.96M |
| Total Equity | 0 | - | 9.82M | 16.30M | 47.90M | 204.15M |
| Shares Outstanding | - | - | 35.91M | 48.92M | 72.07M | 111.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -2.94M | -5.41M | -16.70M | -37.78M |
| Investing Cash Flow | -4.47M | -2.45M | -11.37M | -110.79M |
| Financing Cash Flow | 6.64M | 13.39M | 82.53M | 371.60M |
| Capital Expenditure | -4.47M | -2.33M | -11.37M | -9.65M |
| Free Cash Flow | -7.41M | -7.74M | -28.07M | -47.43M |
| Net Change in Cash | -772.00K | 5.52M | 54.47M | 223.03M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | 32.1% | 38.6% | 14.3% |
| Operating Margin % | - | -3,704.6% | -636.0% | -239.8% |
| Net Margin % | - | -3,761.0% | -780.3% | -734.2% |
| ROE % | -50.4% | -99.9% | -67.5% | -85.8% |
| ROCE % | -48.3% | -73.4% | -30.2% | -12.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.61% | 8.33M | $39.14M |
| 2 | Encompass Capital Advisors, LLC | 5.49% | 6.91M | $32.49M |
| 3 | Vanguard Capital Management LLC | 4.02% | 5.06M | $23.78M |
| 4 | Rovida Investment Management Ltd | 3.26% | 4.10M | $19.27M |
| 5 | UBS Group AG | 2.26% | 2.84M | $13.36M |
| 6 | Geode Capital Management, LLC | 2.18% | 2.74M | $12.88M |
| 7 | Alyeska Investment Group, L.p. | 2.14% | 2.69M | $12.65M |
| 8 | State Street Corporation | 1.84% | 2.32M | $10.91M |
| 9 | Exchange Traded Concepts LLC | 1.73% | 2.18M | $10.26M |
| 10 | AWM Investment Company, Inc. | 1.69% | 2.12M | $9.99M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ASPI
ASP Isotopes Announces Agreements to Exchange Certain QLE Convertible Notes for ASPI Common Stock
Exchange reduces QLE’s outstanding convertible notes by approximately 50% as QLE continues to pursue a public listing as a separate companyDALLAS, July 15, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASPI", the "Company" or …
CRML, UUUU, ASPI, USAR In Focus: Report Questions Trump, Lutnick Family Ties To Government-Backed Critical Metal Projects
Concerns have been raised about companies pursuing more than $8.9 billion in federal support.
Alliance Entertainment and ASP Isotopes Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / June 26, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and ASP Isotopes, Inc. (Nasdaq:ASPI) on the RedChip Small Stocks, Big Money™show, a sponsored prog…
Top Midday Decliners
ASP Isotopes (ASPI) said Thursday its Noble Africa unit will merge with a subsidiary of Endra Life S
ASP Isotopes To Merge Noble Africa With A Unit Of ENDRA – A Look At The Key Contours Of The Deal
ASP Isotopes is expected to own approximately 89% of the combined company, with ENDRA shareholders owning 3%.
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
DALLAS & ANN ARBOR, Mich., June 25, 2026--ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," "ASPI" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials us…
ASPI — Frequently Asked Questions
What is the current share price of ASP Isotopes Inc. (ASPI)?
As of 2026-07-15 16:51 PDT, ASP Isotopes Inc. (ASPI) trades at $4.58 on NasdaqCM. Its 52-week range is $4.07 to $14.05.
What is the market capitalisation of ASPI?
ASP Isotopes Inc. (ASPI) has a market capitalisation of $576.64M on NasdaqCM.
What is the P/E ratio of ASPI?
ASPI trades at a trailing price-to-earnings (P/E) ratio of -2.07. The industry average P/E is 23.08. Its price-to-book (P/B) ratio is 2.05.
What is the return on equity (ROE) of ASPI?
ASPI has a return on equity (ROE) of -103.32%. Its return on capital employed (ROCE) is -12.29%.
Is ASPI a good stock to buy?
This page provides a data-driven analysis of ASP Isotopes Inc. (ASPI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.